The FDA has accepted the NDA for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

Lexicon said that its near-term focus will be on its drug candidate LX9211 for diabetic neuropathic pain, with topline Phase ...

Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy ... All forward-looking statements are based ...

Albuquerque Acupuncture and Integrative Medicine is a local clinic that specializes in treating complex chronic illnesses, ...

Fintel reports that on December 20, 2024, BMO Capital downgraded their outlook for Biogen (NasdaqGS:BIIB) from Outperform to ...

Most of us never give our gallbladder a second thought-until it causes trouble. This small, pear-shaped organ located in your ...

Discover the truth with our in-depth NervoVive reviews—uncover whether it's a scam or the ultimate solution for nerve health!

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...